TICKERNERD
Menu
INTSINTSHealthcare · Biotechnology

INTS Stock Forecast: Intensity Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 13 Oct 2026
$3.55
+7.25% on the day

The 6 Wall Street analysts covering Intensity Therapeutics, Inc. hold a median 12-month price target of $18 — +393.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 13 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$10.8M
Ticker Nerd rank
30 / 100
Median analyst target
$18
Analysts covering
6
Revenue$0.0
Operating income−$3.1M
Net income−$3.0M
Free cash flow−$2.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
0.0%
1M
−11.7%
YTD
−65.4%
1Y
−52.7%
From 52W high
−89.2%
From 52W low
+10.6%
$3
$33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Intensity Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Oct 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
91
Growth
65
Volatility
64
Accruals
44
Momentum
33
Issuance
31
Revisions
29
Value
26
Quality
23

Size (91): Smaller than most of the companies we track.

Quality (23): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INTS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30$35Jan 26Apr 26Jul 26Oct 26INTSHigh $32Median $18Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $7Median $18High $32

The green dot is the last close — the median target sits +393.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Aug 2026HC Wainwright & Co.MaintainsBuy$5.00 → $7.00
20 Aug 2025BenchmarkMaintainsSpeculative Buy$4.00 → $1.50
20 Aug 2025BenchmarkMaintainsSpeculative Buy—
12 Aug 2025Brookline CapitalUpgradeBuy—
13 Jan 2025Alliance Global PartnersInitiatesBuy—
21 Nov 2024HC Wainwright & Co.ReiteratesBuy—
31 Oct 2024HC Wainwright & Co.InitiatesBuy—
11 July 2024BenchmarkReiteratesSpeculative Buy—
16 May 2024BenchmarkReiteratesSpeculative Buy—
21 Mar 2024BenchmarkReiteratesSpeculative Buy—
14 Nov 2023BenchmarkReiteratesSpeculative Buy—
24 Aug 2023BenchmarkReiteratesSpeculative Buy—
18 July 2023BenchmarkInitiatesSpeculative Buy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INTS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

INTS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Oct 2026, Intensity Therapeutics, Inc. returned −52.7% against +18.6% for the S&P 500, dividends included.

INTS vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26INTSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Intensity Therapeutics, Inc. (INTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 80% of US stocks

Price / sales
—
Price / book
1.0×

Cheaper than 71% of US stocks

EV / EBITDA
−0.1×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−195.9%

Higher than 7% of US stocks

Return on assets
−89.9%

Higher than 3% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Intensity Therapeutics, Inc. (INTS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Intensity Therapeutics, Inc. has a market value of $10.8M and an enterprise value of $1.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$11.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$9.0M.

  • Shares outstanding: 2.9M.

  • Trailing P/E: −0.4×; forward P/E: −1.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Intensity Therapeutics, Inc. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

INTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INTSIntensity Therapeutics, Inc.$10.8M
30
PLURPluri, Inc.$11.6M
14
INABIN8bio, Inc.$11.5M
56
TPSTTempest Therapeutics, Inc.$11.5M
45
PASGPassage Bio, Inc.$11.7M
44
AEONAEON Biopharma, Inc.$11.5M
51
ACTUActuate Therapeutics, Inc.$11.2M
34

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Intensity Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INTS news & analysis

Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 8 Sept 2026neutral

Intensity Therapeutics, Inc. announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The company, a late-stage clinical biotechnology firm developing intratumoral cancer therapies, shared the news via press release on September 8, 2026.

Why it matters — Conference participation gives INTS investors an opportunity for company management to present its clinical programs and engage with the investment community, potentially raising visibility for the stock.

Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for Intensity Therapeutics, Inc. (INTS), covering the company's quarterly earnings presentation and discussion.

Why it matters — INTS watchers can review management's Q2 2026 commentary from the official earnings call transcript.

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

PRNewsWire · 11 Aug 2026neutral

Intensity Therapeutics reported second quarter 2026 financial results, with cash and cash equivalents of $9.5 million as of June 30, 2026. The company began activities to resume enrollment at a limited number of U.S. sites in the Phase 3 INVINCIBLE-3 soft tissue sarcoma study by Q3 2026, restarted patient treatment in the Phase 2 INVINCIBLE-4 presurgical triple negative breast cancer study, and increased business development activities.

Why it matters — This update signals resumed clinical progress across two key trials and a modest cash position, which INTS watchers would track as important catalysts for the company's pipeline.

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

PRNewsWire · 4 Aug 2026neutral

Intensity Therapeutics announced it will report its second quarter 2026 financial results before the market opens on August 11, 2026, and will hold a conference call at 8AM ET that day to review the results and provide a corporate update.

Why it matters — The upcoming earnings release and conference call will give INTS watchers their latest update on the company's financials and clinical-stage business.

FAQ

Frequently asked questions about INTS stock

What is the INTS stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Intensity Therapeutics, Inc. have a median 12-month price target of $18, with estimates ranging from $7 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INTS stock a buy right now?

Of the 6 analysts covering Intensity Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Intensity Therapeutics, Inc. 30 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INTS?

As at 13 Oct 2026, Intensity Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

Will INTS stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +393.0% from the last close, and Ticker Nerd's factor model ranks Intensity Therapeutics, Inc. 30 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INTS stock forecast for 2030?

No analyst covering Intensity Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $32 over the next 12 months.

How has INTS stock performed over the past year?

Intensity Therapeutics, Inc. returned -52.7% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Intensity Therapeutics, Inc. do?

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on developing intratumoral cancer therapies for solid tumors.

What is the latest news on INTS?

The most recent item we track (PRNewsWire, 8 Sept 2026): "Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference". Intensity Therapeutics, Inc. announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The company, a late-stage clinical biotechnology firm developing intratumoral cancer therapies, shared the news via press release on September 8, 2026.

Company

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on developing intratumoral cancer therapies for solid tumors. Its lead product candidate, INT230-6, is designed to be injected directly into tumors to help destroy cancer cells locally while also promoting a broader immune response against cancer throughout the body. The company’s platform centers on proprietary drug-conjugation technology that combines active anti-cancer agents with molecules that improve dispersion within tumors and cellular uptake. Intensity Therapeutics is currently advancing programs in cancers such as soft tissue sarcoma and triple-negative breast cancer, with an emphasis on addressing both localized disease and metastatic spread. Headquartered in Shelton, Connecticut, Intensity Therapeutics operates within the oncology biotechnology segment, where its work contributes to the development of novel immune-based treatment approaches for patients with solid tumor cancers.

CEO Mr. Lewis H. Bender M.A., M.B.A., M.S. · 5 employees · United States · https://intensitytherapeutics.com